Provision of medical care is classified into primary, secondary, and tertiary care categories.
Primary care medical services are health care given by healthcare providers: physicians, a professional who practices medicine, who is concerned with promoting, maintaining or restoring human health through the study, diagnosis, and treatment of disease, injury, and other physical and mental impairments; physician assistants (PA), a healthcare professional who is trained to practice medicine under the supervision of a physician; nurse practitioners (NP), advanced practice registered nurses (APRN) who have completed graduate-level education (either a Master of Nursing or Doctor of Nursing Practice degree); or other health professionals who have first contact with a patient seeking medical treatment or care. These occur in: physician offices; clinics (“outpatient clinics” or “ambulatory care clinics”), health care facilities that are primarily devoted to the care of outpatients; nursing homes (“convalescent homes,” “skilled nursing facilities” (“SNF”), “care home,” “rest home,” “intermediate care,” or “old folk’s home”), which provide a type of residential care; schools, home visits, and other places close to patients.
About 90% of medical visits can be treated by the primary care provider. These include treatment of: acute and chronic illnesses; preventive care/medicine, consisting of measures taken to prevent diseases (or injuries), rather than curing them or treating their symptoms; and health education, the profession of educating people (all ages and both sexes) about health.
Secondary care (“healthcare”) medical services, the diagnosis, treatment, and prevention of disease, illness, injury, and other physical and mental impairments in humans, are provided by medical specialists in their offices or clinics or at a local community hospitals for a patient referred by a primary care provider who first diagnosed or treated the patient. Referrals are made for those patients who required the expertise or procedures performed by specialists. These include both: ambulatory care, a personal health care consultation, treatment or intervention using advanced medical technology or procedures delivered on an “outpatient” basis (i.e. where the patient’s stay at the hospital or clinic, from the time of registration to discharge, occurs on a single calendar day); and inpatient services, or when a patient is “admitted” to the hospital and stays overnight or for an indeterminate time, usually several days or weeks (though some cases, such as coma patients, have been in hospitals for years). Others are: emergency rooms (“emergency department” (“ED”), “accident & emergency” (A&E”), “casualty department”), or “ER,” a medical treatment facility specializing in acute care of patients who present without prior appointment, either by their own means or by ambulance; intensive/critical-care medicine, a branch of medicine concerned with the diagnosis and management of life-threatening conditions requiring sophisticated organ support and invasive monitoring; surgery services; physical therapy (“physiotherapy”), often abbreviated “PT,” a health care profession primarily concerned with the remediation of impairments and disabilities and the promotion of mobility, functional ability, quality of life and movement potential through examination, evaluation and physical intervention carried out by “physical therapists” (known as “physiotherapists” in some countries) and “physical therapist assistants” (known as “physical rehabilitation therapists” in some countries); labor and delivery (“childbirth,” also called “partus” or Parturition”), the culmination of a human pregnancy or gestation period with the expulsion of one or more newborn infants from a woman’s uterus; endoscopy units, with endoscopy meaning “looking inside” and typically refers to looking inside the body for medical reasons using an “endoscope,” an instrument used to examine the interior of a hollow organ or cavity of the body; hospice centers, or centers for a type of care and a philosophy of care that focuses on the palliation of a terminally ill or seriously ill patient’s symptoms; diagnostic/medical/clinical laboratory, or a laboratory where tests are done on clinical specimens in order to get information about the health of a patient as pertaining to the diagnosis, treatment, and prevention of disease; and medical imaging services, the technique and process used to create images of the human body (or parts and functions thereof) for clinical purposes (medical procedures seeking to reveal, diagnose, or examine disease) or medical science (including the study of normal anatomy and and physiology; etc. Some primary care providers may also take care of hospitalized patients and deliver babies in a secondary care setting.
Tertiary care medical services, specialized consultative health care, usually for inpatients and on referral from a primary or secondary health professional, in a facility that has personnel and facilities for advanced medical investigation and treatments, such as tertiary referral hospital, are provided by specialist hospitals or regional centers equipped with diagnostic and treatment facilities not generally available at local hospitals. These include: trauma centers, a hospital equipped to provide comprehensive emergency medical services to patients suffering traumatic injuries; burn treatment centers, for a type of injury to flesh caused by heat, electricity, chemicals, light, radiation or friction; advanced neonatology unit service, a subspecialty of pediatrics that consists of the medical care of newborn infants, especially the ill or premature newborn infant; organ transplants, the moving of an organ from one body to another or from a donor site to another location on the patient’s own body, for the purpose of replacing the recipient’s damaged or absent organ; high-risk pregnancy; radiation oncology/therapy (“radiotherapy”), sometimes abbreviated to XRT or DXT, the medical use of ionizing radiation, generally as part of cancer treatment to control or kill malignant cells; etc.
Modern medical care also depends on information--still delivered in many health care setting in paper records, but increasingly nowadays by electronic means.
See: SpaceX CRS-1's Mission Plan: Flight day 4 and remainder of mission by John Diaz
Ipinapakita ang mga post na may etiketa na John Diaz. Ipakita ang lahat ng mga post
Ipinapakita ang mga post na may etiketa na John Diaz. Ipakita ang lahat ng mga post
Linggo, Enero 6, 2013
Medical Institutions' Delivery
Mga etiketa:
John Diaz,
Medical Institutions' Delivery,
mission plan,
SpaceX CRS-1
Lunes, Oktubre 15, 2012
The Professional Career of Shinya Yamanaka, 2012 Nobel Prize Awardee by John Diaz
Shinya Yamanaka is a Japanese physician and researcher of adult stem cells, or biological cells found in all multicellular organisms, that can divide through mitosis and differentiate into diverse specialized cell types and can self-renew to produce more stem cells.
Yamanaka serves as the director of Center for iPS Cell Research and Application and a professor at the Institute for Frontier Medical Sciences at Kyoto University, or “Kyodai,” a national university located in Kyoto, Japan; and as a professor of anatomy at University of California, San Francisco (UCSF), a center of health sciences research, patient care, and education, located in San Francisco, California. He is also the current president of the International Society for Stem Cell Research (ISSCR).
In 2011, he received the Wolf Prize in Medicine, awarded once a year by the Wolf Foundation in Israel, with Rudolf Jaenisch, a biologist at MIT. This year, he won two prizes: the Millenium Technology Prize, the largest technology prizes in the world, together with Linus Torvalds, a Finnish American software engineer and hacker, who has the principal force behind the development of the Linux kernel; and the Nobel Prize in Physiology or Medicine, administered by the Nobel Foundation, awarded once a year for outstanding discoveries in the fields of life sciences and medicine, together with John B. Gurdon.
Between 1987 and 1989, Yamanaka was a resident in orthopedic surgery at the National Osaka Hospital. From 1993 to 1996, he was at the Gladstone Institute of Cardiovascular Disease, an independent and nonprofit biomedical research organization whose focus is to better understand, prevent, treat and cure cardiovascular, viral and neurological conditions such as heart failure, HIV/AIDS and Alzheimer’s disease; which is affiliated with the University of California, San Francisco (“UCSF”), a center of health sciences research, patient care, and education, located in San Francisco.
Between 1996 and 1999, he was an assistant professor, which is generally a rank held for a probationary period of three to seven years, after which the individual must either earn tenure and promotion to associate professor or find other employment, at the Nara Institute of Science and Technology, abbreviated as NAIST, a Japanese national university located in Ikoma, Nara of Kansai Science City. During 2003-2005, he was a professor at the Nara Institute of Science and Technology. Between 2004 and 2010, Yamanaka was a professor at the Institute for Frontier Medical Sciences. Currently, Yamanaka is the director and a professor at the Center for iPS Cell Research and Application in Kyoto University, Japan.
In 2006, he and his team induced pluripotent stem cells (iPS cells), a type of pluripotent stem cell artificially derived from a non-pluripotent cell--typically an adult somatic cell--by inducing a “forced” expression of specific genes, from adult mouse fibroblasts, a type of cell that synthesizes the extracellular matrix and collagen, the structural framework (stroma) for animal tissues, and plays a critical role in wound healing.
iPS cells closely resemble embryonic stem cells (“ES cells”), pluripotent stem cells derived from the inner cell mass of the blastocyst, an early-stage embryo, the “in vitro” equivalent of the part of the blastocyst, a structure formed in the early development of vertebrates (the embryo a few days after fertilization), which grows to become which the embryo proper. They could show that his iPS cells were pluripotent, which in cell biology, refers to a stem cell that has the potential to differentiate into any of the three germ layers: endoderm (interior stomach lining, gastrointestinal tract, the lungs), mesoderm, (muscle (muscle, bone, blood, urogenital), or ectoderm (epidermal tissues and nervous system); i.e. capable of generating all cell lineages of the body, and were soon after capable of generating mice from iPS cells.
In 2007, he and his team generated iPS cells from human adult fibroblasts, again as the first group to do so. A key difference from previous attempts by the field was his team’s use of multiple transcription factors (sometimes called a sequence-specific DNA-binding factor), which in molecular biology and genetics, is a protein that binds to specific DNA sequences, thereby controlling the flow (or transcription) of genetic information from DNA to mRNA. It is instead of transfecting, or the process deliberately introducing nucleic acids into cells, one transcription factor per experiment.
They started with 24 transcription factors known to be important in the early embryo, but could in the end reduce it to four transcription factors--SoX2, also known as “SRY (sex determining region-Y)-box 2, a transcription factor that is essential for maintaining self-renewal and pluripotency, of undifferentiated embryonic stem cells; Oct4 (octamer-binding transcription factor 4), also known as “POU5F1” (POU domain, class 5, transcription factor 1), a protein that in humans is encoded by the “POU5F1” gene; Klf4 (“Kruppel-like factor 4”), a protein that in humans is encoded by the “KLF4” gene; and, c-Myc (“Myc”), a regulator gene that codes for a transcription factor.
See: VSAT Internet on Satellite Services
Yamanaka serves as the director of Center for iPS Cell Research and Application and a professor at the Institute for Frontier Medical Sciences at Kyoto University, or “Kyodai,” a national university located in Kyoto, Japan; and as a professor of anatomy at University of California, San Francisco (UCSF), a center of health sciences research, patient care, and education, located in San Francisco, California. He is also the current president of the International Society for Stem Cell Research (ISSCR).
In 2011, he received the Wolf Prize in Medicine, awarded once a year by the Wolf Foundation in Israel, with Rudolf Jaenisch, a biologist at MIT. This year, he won two prizes: the Millenium Technology Prize, the largest technology prizes in the world, together with Linus Torvalds, a Finnish American software engineer and hacker, who has the principal force behind the development of the Linux kernel; and the Nobel Prize in Physiology or Medicine, administered by the Nobel Foundation, awarded once a year for outstanding discoveries in the fields of life sciences and medicine, together with John B. Gurdon.
Between 1987 and 1989, Yamanaka was a resident in orthopedic surgery at the National Osaka Hospital. From 1993 to 1996, he was at the Gladstone Institute of Cardiovascular Disease, an independent and nonprofit biomedical research organization whose focus is to better understand, prevent, treat and cure cardiovascular, viral and neurological conditions such as heart failure, HIV/AIDS and Alzheimer’s disease; which is affiliated with the University of California, San Francisco (“UCSF”), a center of health sciences research, patient care, and education, located in San Francisco.
Between 1996 and 1999, he was an assistant professor, which is generally a rank held for a probationary period of three to seven years, after which the individual must either earn tenure and promotion to associate professor or find other employment, at the Nara Institute of Science and Technology, abbreviated as NAIST, a Japanese national university located in Ikoma, Nara of Kansai Science City. During 2003-2005, he was a professor at the Nara Institute of Science and Technology. Between 2004 and 2010, Yamanaka was a professor at the Institute for Frontier Medical Sciences. Currently, Yamanaka is the director and a professor at the Center for iPS Cell Research and Application in Kyoto University, Japan.
In 2006, he and his team induced pluripotent stem cells (iPS cells), a type of pluripotent stem cell artificially derived from a non-pluripotent cell--typically an adult somatic cell--by inducing a “forced” expression of specific genes, from adult mouse fibroblasts, a type of cell that synthesizes the extracellular matrix and collagen, the structural framework (stroma) for animal tissues, and plays a critical role in wound healing.
iPS cells closely resemble embryonic stem cells (“ES cells”), pluripotent stem cells derived from the inner cell mass of the blastocyst, an early-stage embryo, the “in vitro” equivalent of the part of the blastocyst, a structure formed in the early development of vertebrates (the embryo a few days after fertilization), which grows to become which the embryo proper. They could show that his iPS cells were pluripotent, which in cell biology, refers to a stem cell that has the potential to differentiate into any of the three germ layers: endoderm (interior stomach lining, gastrointestinal tract, the lungs), mesoderm, (muscle (muscle, bone, blood, urogenital), or ectoderm (epidermal tissues and nervous system); i.e. capable of generating all cell lineages of the body, and were soon after capable of generating mice from iPS cells.
In 2007, he and his team generated iPS cells from human adult fibroblasts, again as the first group to do so. A key difference from previous attempts by the field was his team’s use of multiple transcription factors (sometimes called a sequence-specific DNA-binding factor), which in molecular biology and genetics, is a protein that binds to specific DNA sequences, thereby controlling the flow (or transcription) of genetic information from DNA to mRNA. It is instead of transfecting, or the process deliberately introducing nucleic acids into cells, one transcription factor per experiment.
They started with 24 transcription factors known to be important in the early embryo, but could in the end reduce it to four transcription factors--SoX2, also known as “SRY (sex determining region-Y)-box 2, a transcription factor that is essential for maintaining self-renewal and pluripotency, of undifferentiated embryonic stem cells; Oct4 (octamer-binding transcription factor 4), also known as “POU5F1” (POU domain, class 5, transcription factor 1), a protein that in humans is encoded by the “POU5F1” gene; Klf4 (“Kruppel-like factor 4”), a protein that in humans is encoded by the “KLF4” gene; and, c-Myc (“Myc”), a regulator gene that codes for a transcription factor.
See: VSAT Internet on Satellite Services
Mga etiketa:
2012 Nobel Prize Awardee,
Internet on Satellite Services,
John Diaz,
Newsat,
The Professional Career of Shinya Yamanaka,
VSAT
Mag-subscribe sa:
Mga Post (Atom)
